TRYPOBASE

Nucleobase derivatives as drugs against trypanosomal diseases

Coordinatore	AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS    more  Organization address address: CALLE SERRANO 117 city: MADRID postcode: 28006 contact info Titolo: Mr. Nome: Alberto Cognome: Sereno Alvarez Email: send email Telefono: +34 915668852 Fax: +34 915668913
Nazionalità Coordinatore	Spain [ES]
Totale costo	3˙542˙209 €
EC contributo	2˙557˙187 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-B
Funding Scheme	CP-SICA
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-01-01   -   2012-06-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS  Organization address address: CALLE SERRANO 117 city: MADRID postcode: 28006 contact info Titolo: Mr. Nome: Alberto Cognome: Sereno Alvarez Email: send email Telefono: +34 915668852 Fax: +34 915668913	ES (MADRID)	coordinator	615˙665.00
2	UNIVERSITY OF DUNDEE  Organization address address: Nethergate city: DUNDEE postcode: DD1 4HN contact info Titolo: Ms. Nome: Zoe Cognome: Kidd Email: send email Telefono: +44 1382 86240 Fax: +44 1382385438	UK (DUNDEE)	participant	508˙354.00
3	UNIVERSITY OF YORK  Organization address address: HESLINGTON city: YORK NORTH YORKSHIRE postcode: YO10 5DD contact info Titolo: Mr. Nome: Chris Cognome: Barber Email: send email Telefono: +44 1904 434416 Fax: +44 1904 329266	UK (YORK NORTH YORKSHIRE)	participant	349˙658.00
4	SCHWEIZERISCHES TROPEN- UND PUBLIC HEALTH-INSTITUT  Organization address address: SOCINSTRASSE 57 city: Basel postcode: CH-4002 contact info Titolo: Mr. Nome: Ulrich Cognome: Wasser Email: send email Telefono: +41 61 284 8253 Fax: +41 61 284 8101	CH (Basel)	participant	294˙312.00
5	SYNGENE INTERNATIONAL LIMITED PLC  Organization address address: JIGANI LINK ROAD city: BANGALORE postcode: 560 099 contact info Titolo: Mr. Nome: M. B. Cognome: Chinappa Email: send email Telefono: +91 80 2808 3901 Fax: +91 80 28083150	IN (BANGALORE)	participant	280˙200.00
6	INSTITUT PASTEUR DE MONTEVIDEO  Organization address address: MATAOJO 2020 city: MONTEVIDEO postcode: 11400 contact info Titolo: Mr. Nome: Didier Cognome: Pouzergues Email: send email Telefono: 598 2 5220910 ext 105 Fax: 598 2 5224185	UY (MONTEVIDEO)	participant	279˙399.00
7	MEDIVIR AB  Organization address address: Lunastigen 7 city: Huddinge postcode: 14144 contact info Titolo: Dr. Nome: Nils Gunnar Cognome: Johansson Email: send email Telefono: +46 854683115 Fax: +46 854683199	SE (Huddinge)	participant	229˙599.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The protozoan diseases, leishmaniasis, African trypanosomiasis and Chagas’ disease are responsible for substantial global morbidity, mortality, and economic adversity, and in most countries, existing strategies for control and treatment are either failing or under serious threat. New tools for combating pathogenic protozoa and the development and exploitation of new drug targets are required. This proposal builds on several achievements and observations of the consortium in the area of nucleotide metabolism. •Pyrimidine and purine metabolism exhibits unique features in trypanosomes. •The identification of a unique enzyme involved in pyrimidine metabolism restricted to trypanosomes and essential for viability: the dimeric all-alpha dUTPase. •An exceptional collection of purine and pyrimidine analogues is available through the consortium for antiprotozoal screening and lead identification. •The consortium brings together an outstanding combination of expertise for drug discovery. The main objective is the identification of new purine and pyrimidine derivatives for the treatment of the leishmaniases and trypanosomiases. A two-pronged approach is proposed to discover new leads for the treatment of leishmaniasis and trypanosomiasis targeting nucleoside/ nucleotide metabolism. 1)The phenotypic approach exploring the potential of large collections of novel nucleobase derivatives against trypanosomal diseases. 2)The target-based approach specifically centred on the development of inhibitors of the enzyme deoxyuridine triphosphate nucleotidohydrolase. The trypanosomal enzyme shows structural and functional characteristics which differ profoundly from the mammalian counterpart. The aim is to identify potent inhibitors that are active against parasitic protozoa, active in rodent models of infection and have drug-like properties.'

Introduzione (Teaser)

Experts in parasite biology and medicinal chemistry teamed up to identify compounds with potent activity against protozoa of the Trypanosomatidae family. Strategies that intervened with the basic metabolism of DNA in these protozoa were explored.